Awareness to Osteopenia's Treatment by Bisphosphonate in Male Suffering From Prostate Cancer

Title: Increase Awareness to Osteopenia/Osteoporosis Treatment of Patients With Prostate Cancer, by Bisphosphonate Therapy - Registry.

Patients with prostate cancer treated in outpatient clinics will be recruited by their urologist physician.

Primary Objective: To evaluate the compliance in male patients with prostate cancer treated with Bisphosphonate and that suffered from Osteopenia/osteoporosis.

Secondary objectives:

To evaluate the compliance of family physicians to prescribe Bisphosphonate for patients upon recommendation by Urologists.

To evaluate the overall number of patients treated by Bisphosphonate in the out-patient clinics, To evaluate incidence of osteopenia/osteoporosis in this study population.

Inclusion Criteria:

• Man with Prostate Cancer
• Men ≥70 years old or ≥60 years old treated by LH-RH agonist for at least 2 years or Man who was diagnosed in the past with Osteopenia/osteoporosis
• Osteopenia/osteoporosis proven by bone density test.

Exclusion Criteria:

• Creatinine clearance < 30ml/min
• Hypercalcemia
• Actual treatment by Bisphosphonate or steroids
• Hypersensibility to Bisphosphonate or any contraindication to its use.
• Metastatic prostate Cancer
• Patients not suitable for compliance.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.